2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - La Nouvelle C
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Palliative Care, Clinical Practice (Health Services and Quality), Quality of Care, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

151 Duffy Null Phenotype in multiple myeloma: Prevalence and Association with Lenalidomide Dose Reduction during Induction

Iyra Chandra, BS, Wei Sha, PhD2, Rupali Bose, MS,MBA3, Hana Kurz, PharmD, BCOP4, Jessica McElwee, PharmD5, Grace Elsey, PharmD6, Belinda Avalos, MD7, Edward Copelan, MD8, Manisha Bhutani, MD9, Amy Soni, MD10
1 Wake Forest University School of Medicine, Charlotte, United States
2 Atrium Health Levine Cancer Institute, Charlotte, United States
3 Atrium Health Levine Cancer Institute, Charlotte, United States
4 Atrium Health Levine Cancer Institute, Charlotte, United States
5 Atrium Health Levine Cancer Institute, Charlotte, United States
6 Atrium Health Levine Cancer Institute, Charlotte, United States
7 Atrium Health Levine Cancer Institute, Charlotte, United States
8 Atrium Health Levine Cancer Institute, Charlotte, United States
9 Atrium Health Levine Cancer Institute, Charlotte, United States
10 Atrium Health Levine Cancer Institute, Charlotte, United States

Introduction: The Duffy Null phenotype (DN) (Fy[a–b–]), in which red blood cells lack the Duffy glycoprotein, has been described in approximately two thirds of patients who self-identify as African American (AA). DN is associated with a lower absolute neutrophil count (ANC) and white blood cell (WBC) count with no increased incidence of infection. DN-specific ANC reference intervals are well below conventional institutional ranges, so standard thresholds misclassify many healthy DN individuals as neutropenic. In multiple myeloma (MM), lenalidomide dosing is modified according to ANC, meaning DN could prompt unnecessary treatment attenuation even in the absence of true myelosuppression. There is reported enrichment of DN in triple-negative breast cancer, and this may hold true for other malignancies, including MM. In this study, we assessed whether DN prevalence differs between AA patients with and without MM, and whether DN is associated with lenalidomide dose reduction during induction.

Methods: Data were sourced from a retrospective in-house MM database. Serologic Duffy typing, defining DN as Fy(a–b–), was implemented as standard of care in May 2026 and performed irrespective of complete blood count results, self-reported race, or treatment history. DN status in non-MM comparators was obtained from a single primary care center as part of the ASH ANC by Duffy Status Project. Induction was defined as therapy within 6 months of diagnosis, and any lenalidomide dose reduction relative to the initiation dose during induction therapy was analyzed as a variable. DN prevalence in AA patients with versus without MM was compared using a two-sided Fisher exact test. A separate age-adjusted logistic model evaluated the association between DN and lenalidomide dose reduction.

Results: As of the July 2026 data cutoff, 133 patients had completed DN testing and formed the prevalence cohort.  Of these, 93 had initiated lenalidomide-based induction with documented dosing and formed the dose-reduction cohort. Accrual is ongoing. Among evaluable patients of any race with MM, 65 of 133 (48.9%) had DN. Baseline characteristics of MM population were as follows: Median age: 62, AA race: 63.9% (85/133), female: 47.4% (63/133).  Of the 85 AA patients with MM, 64 (75.3%) had DN, similar to the 73 of 103 (70.9%) AA patients seen at primary care clinic without MM (P = 0.515). Mean baseline WBC for DN MM patients vs non-DN patients was 4.93x10^3 vs 5.39x10^3, and ANC was 2.85x10^3 vs 3.48x10^3, respectively.  After 4 months on induction therapy including lenalidomide, mean WBC for DN vs. non-DN patients was 4.28x10^3 vs 5.10x10^3, and ANC was 2.62x10^3 vs 3.41x10^3.  Any dose reduction of lenalidomide induction therapy occurred in 5 of 44 (11.4%) non-DN patients and 7 of 49 (14.3%) DN patients. In an age-adjusted model, DN was not associated with dose reduction (OR 1.43, 95% CI: 0.41–5.00; P = 0.573).

Conclusion: In this interim cohort, DN prevalence among AA patients with MM was similar to that of AA patients without MM, providing no evidence of enrichment in MM.  DN status was not associated with lenalidomide dose reduction during induction, suggesting that a DN-specific ANC alone may not lead to treatment modification.  Given that DN status was generally unknown to treating clinicians during induction, these findings suggest that conventional ANC thresholds did not disproportionately prompt dose reduction in DN patients. Limitations of the study include the fact that relative dose intensity of lenalidomide was not analyzed in this interim dataset; dose delays, growth factor support, and infection events were not captured; and the analysis was restricted to induction lenalidomide at a single institution, without evaluation of maintenance therapy or other MM agents. Nonetheless, nearly half of patients treated for MM at our center have DN, and knowledge of this condition may inform clinical decision-making even when medication dosing is not significantly impacted. Ongoing work will incorporate relative dose intensity, growth factor use, infection, and survival endpoints, toward prospective evaluation of DN-informed ANC thresholds. This work builds on emerging literature advocating for DN-adjusted ANC thresholds to reduce unnecessary dose modifications, increase the inclusion of DN patients in clinical trials, and improve treatment outcomes and equity for patients affected by racial and ethnic disparities.

Iyra Chandra, BS: No relevant conflicts of interest to declare.